Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07636772 Ivonescimab Advanced Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07636772 Ivonescimab Advanced Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07636772 clinical trial report covering Ivonescimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262219 HYZ2001 Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262219 HYZ2001 Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262219 clinical trial report covering HYZ2001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07634536 Fludarabine Phosphate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07634536 Fludarabine Phosphate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07634536 clinical trial report covering Fludarabine Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07635563 Acetazolamide/Dronabinol Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07635563 Acetazolamide/Dronabinol Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07635563 clinical trial report covering Acetazolamide/Dronabinol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07635524 61Cu-NU-101 Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07635524 61Cu-NU-101 Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07635524 clinical trial report covering 61Cu-NU-101, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07637006 Ocimum Gratissimum Extract/Calcium carbonate/Aluminum hydroxide/Magnesium Trisil Metabolic dysfunction-associated steatotic liver disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07637006 Ocimum Gratissimum Extract/Calcium carbonate/Aluminum hydroxide/Magnesium Trisil Metabolic dysfunction-associated steatotic liver disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07637006 clinical trial report covering Ocimum Gratissimum Extract/Calcium carbonate/Aluminum hydroxide/Magnesium Trisil, Phase 2, endpoints, sponsor, g
Read →
NCT07636356 Tetrahydrocannabivarin Smoking Cessation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07636356 Tetrahydrocannabivarin Smoking Cessation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07636356 clinical trial report covering Tetrahydrocannabivarin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07636564 Cyclophosphamide leukemia acute ambiguous lineage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07636564 Cyclophosphamide leukemia acute ambiguous lineage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07636564 clinical trial report covering Cyclophosphamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07634601 Everolimus Metastatic endometrial cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07634601 Everolimus Metastatic endometrial cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07634601 clinical trial report covering Everolimus, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07635862 Ganaxolone Autism Spectrum Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07635862 Ganaxolone Autism Spectrum Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07635862 clinical trial report covering Ganaxolone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07640503 Lamivudine Rett Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07640503 Lamivudine Rett Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640503 clinical trial report covering Lamivudine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600126499 Bevacizumab Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600126499 Bevacizumab Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126499 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →